Vasculitis, Takayasu Arteritis, and Inflammatory Arteriopathies

50.1Definition and presentation

Large-vessel vasculitis is an inflammatory arteriopathy principally encompassing giant cell arteritis and Takayasu arteritis. The conditions present with overlapping ischemic and structural complications, but follow distinct clinical patterns:

• Giant cell arteritis typically presents with cranial or ocular danger, limb ischemia, aortic inflammation, aneurysmal change, or branch-vessel stenosis.
• Takayasu arteritis presents with pulse deficits, arm claudication, renal-artery involvement, cerebrovascular symptoms, coarctation-like aortic narrowing, aneurysm, or malperfusion.

Symptoms, physical signs, and inflammatory markers alone possess limited diagnostic accuracy, necessitating confirmatory imaging or histology GCA Diagnostic Accuracy 2020. Because diagnostic delay increases the risk of irreversible organ damage, empirical medical treatment and diagnostic confirmation proceed concurrently when high-risk features, such as visual symptoms, are present ACR/VF 2021 · EULAR 2018 · Diagnostic Delay 2017.

The Numano (Hata) angiographic classification maps Takayasu distribution: type I, aortic arch branches only; type IIa, ascending aorta, arch, and arch branches; type IIb, IIa plus the thoracic descending aorta; type III, thoracic descending aorta, abdominal aorta, and/or renal arteries; type IV, abdominal aorta and/or renal arteries; type V, combined IIb and IV involving the entire aorta. Coronary (C+) and pulmonary (P+) involvement are appended designators Takayasu Angiographic Types 2025.

50.2Diagnosis and imaging

Imaging selects the modality that answers the immediate clinical question: confirming disease, mapping extent, evaluating active inflammation, defining fixed damage, or planning a procedure EULAR Imaging 2023 · EULAR Imaging SLR 2023 · LVV Imaging Review · 2024. Active vascular inflammation is clinically and radiologically distinct from accumulated structural damage, and an abnormal vessel does not automatically indicate active vasculitis.

• Ultrasound is the recommended first-line imaging test for suspected cranial giant cell arteritis. The key finding is the halo sign, a homogeneous hypoechoic non-compressible wall thickening (positive compression sign) of the temporal and/or axillary arteries; a positive study in a high-probability patient confirms giant cell arteritis without biopsy EULAR Imaging 2023.
• Computed tomography angiography (CTA) provides acute, high-resolution mapping of the lumen, occlusion, thrombus, calcification, aneurysms, and operative landing zones.
• Magnetic resonance angiography (MRA) evaluates the vessel wall and lumen simultaneously, facilitating longitudinal surveillance without iodinated contrast.
• Fluorodeoxyglucose positron emission tomography (FDG-PET) identifies metabolic inflammatory activity and total-body disease distribution, particularly when conventional imaging and clinical symptoms conflict.

Heterogeneous arterial involvement is common, and imaging must differentiate between active remodeling potential and chronic fixed damage before intervention is planned EULAR Imaging 2023 · Takayasu Angiographic Types 2025 · LVV Imaging Review · 2024.

50.3Treatment decision and repair timing

Management prioritizes the control of systemic inflammation before anatomic reconstruction. The timing of repair is a biological decision governed by disease activity, the severity of fixed vascular damage, and the presence of ischemic or aneurysmal threat.

The stepwise logic for managing large-vessel vasculitis relies on qualitative thresholds, as precise timing intervals are not specified in the available guidelines:

1. Decide observation versus treatment. Medical therapy utilizing conventional disease-modifying agents or biologic agents like tocilizumab is established first to halt disease progression Takayasu Tocilizumab 2023 · Takayasu DMARDs 2021. Surveillance is maintained for asymptomatic lesions.
2. Decide medical versus procedural therapy. Intervention is reserved for clinically significant fixed stenosis, aneurysm, or malperfusion that persists despite medical control.
3. Evaluate endovascular suitability. Endovascular repair is preferred for focal stenosis, isolated renal-artery lesions, or high-risk surgical candidates, though active inflammation increases the risk of recoil and restenosis.
4. Evaluate open surgery. Open reconstruction is preferred for long-segment occlusive disease or extensive aneurysms, relying on durable bypass to non-inflamed target vessels. Endarterectomy is generally avoided in diffuse inflammatory disease.
5. Evaluate emergency exceptions. Rupture, critical limb ischemia, and threatened renal, mesenteric, or cerebral perfusion compel immediate intervention before inflammatory control is achieved.

50.4Distinct inflammatory arteriopathies

Large-vessel vasculitis guidelines do not universally apply to peripheral inflammatory arteriopathies. Thromboangiitis obliterans (Buerger disease) and Raynaud-spectrum disorders present with distal or digital ischemia and follow separate disease-specific evidence bases for limb-risk management rather than the Takayasu or giant cell arteritis framework Buerger Outcome 2018. Medium-vessel vasculitis and rare peripheral inflammatory syndromes require distinct medical management and targeted interventions for tissue loss or hemorrhage without direct extrapolation of large-vessel timing principles ACR/VF 2021 · EULAR 2018.

50.5Areas of controversy

Distinguishing postoperative technical failure or fixed damage progression from recurrent inflammatory relapse remains challenging, as markers of clinical and radiological activity frequently overlap EULAR Imaging 2023 · LVV Imaging Review · 2024. Precise quantitative intervals establishing how long medical therapy must be maintained before an elective intervention is biologically safe remain undefined in consensus guidelines. The perioperative management of biologic agents, particularly tocilizumab, lacks robust surgical trial data and relies heavily on broader systemic-control extrapolation Takayasu Tocilizumab 2023.